ENDOCYTE INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|---|
| Revenue | $12,000 | $12,000 | $70,000 | $70.4M | $64.9M | $34.7M |
| Operating income | −$11.7M | −$10.3M | −$42.0M | $5.0M | −$18.3M | −$16.0M |
| Net income | −$11.5M | −$10.2M | −$41.3M | $5.5M | −$18.0M | −$17.3M |
| Total assets | $100.8M | $143.5M | $178.4M | $212.8M | $162.9M | $214.1M |
| Total liabilities | $5.3M | $6.3M | $7.0M | $7.8M | $74.6M | $114.5M |
| Equity | $95.5M | $137.1M | $171.3M | $205.0M | $88.2M | $99.6M |
| EPS (diluted) | — | $-1.04 | $-0.98 | $0.13 | $-0.50 | $-0.48 |
| Shares out. | 42.5M | 42.2M | 41.9M | 36.2M | 35.9M | 35.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- −97725.0%
- Net margin
- −95741.7%
- Return on equity
- −12.0%
- Return on assets
- −11.4%
- Return on capital (ROCE)
- −12.2%
- Liabilities / assets
- 5.2%
- Debt / equity
- 0.06×
- Book value / share
- $2.25
- Revenue growth (YoY)
- 0.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- 14.34safe
- Accruals / assets
- 22.0%high accruals
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteDec 21, 2018
- Other material eventDec 17, 2018
- Other material eventDec 3, 2018
- Results of operationsNov 7, 2018
- Entered a material agreement · Amended charter or bylaws · Regulation FD disclosureOct 18, 2018
- Entered a material agreementSep 12, 2018
- Regulation FD disclosureSep 10, 2018
- Results of operationsJul 31, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.